NCT05716672 - Impact of Lazertinib Dose Modification on Effectiveness and Safety | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Lazertinib

Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity

Trial Locations (11)

Kyungpook National University Chilgok Hospital, Daegu

Kyungpook National University Hospital, Daegu

Yeungnam University Medical Center, Daegu

Daegu Catholic University Medical Center, Daegu

Keimyung University Dongsan Medical Center, Daegu

Inje University Busan Paik Hospital, Busan

Inje University Haeundae Paik Hospital, Busan

Dong-A University Hospital, Busan

Pusan National University Hospital, Busan

Kosin University Gospel Hospital, Busan

Pusan National University Yangsan Hospital, Yangsan

All Listed Sponsors

collaborator

Yuhan Corporation

INDUSTRY

lead

Pusan National University Hospital

OTHER